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Staphylococcus epidermidis is the staphylococci species most commonly associated with bacteremia and hospital-acquired 
infections and has recently arisen as the leading cause of infections related to indwelling medical devices such as vascular 
catheters, prosthetic joints and artificial heart valves. The prevalence of S. epidermidis in hospital-acquired infections is 
due to its ability to adhere and form biofilms on biomaterial surfaces. This feature is one of the most important virulence 
factors found in S. epidermidis. In biofilm form, bacteria are protected from antimicrobial agents and the host immune 
system contributing to the persistence of biofilm infections. In addition, the emergence of S. epidermidis resistance to 
conventional therapies, based in the use of traditional antibiotics, leads to the failure of the current treatments used in the 
combat of S. epidermidis infections and is becoming a major concern. These facts are stimulating the continuous search for 
novel agents able to eradicate S. epidermidis biofilm infections or that can work in synergy with the currently available 
antimicrobial agents. New strategies have been showing encouraging in vitro results in controlling S. epidermidis biofilms 
and seem to be promising alternatives to standard antibiotics usually used in the treatment of S. epidermidis related 
infections. 
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1. General introduction 
The coagulase-negative staphylococci Staphylococcus epidermidis is a human skin commensal microorganism. 
However, this bacterium can become an opportunistic pathogen and as such is often associated with bacteremia and 
hospital acquired infections, particularly in patients with catheters or others medical devices [1]. The main cause of their 
pathogenicity is their ability to adhere and form biofilms on the surfaces of the medical devices formerly mentioned. A 
biofilm is an aggregate of cells adhered to living or non-living surfaces and embedded in a self-produced matrix of 
extracellular polymeric substances (EPS). In biofilm form, bacteria are protected from antimicrobial agents and the host 
immune system contributing to the persistence of biofilm infections, and can be up to 1 000 fold more resistant to 
antibiotics and other antimicrobial agents, than their planktonic counterparts [2-4]. The high resistance presented by 
Staphylococcus epidermidis biofilm cells to antimicrobial agents boosted the persistant demand for new control 
strategies against this pathogenic bacterium in this mode of growth.  
 In fact, new strategies to control S. epidermidis biofilm-mediated infections have attracted the attention of many 
research groups and several studies have and are being done in order to find antimicrobial agents effective against this 
bacterium, specifically in this mode of growth. Natural subtances with possible antimicrobial properties have raised 
researchers’ interest and are pointed as potential alternatives to antibiotics. Some examples are farnesol and other 
terpene alcohols, N-acetylcysteine (NAC), berberine, casbane diterpene, salvipisone, etc. that have been tested as novel 
agents against several pathogenic microorganisms such as bacteria, fungi and also virus, and namely against S. 
epidermidis. The development of adaptative resistance to antibiotics used in common clinical practice has also 
increased the interest on the new generation of antibiotics such as tigecycline, daptomycin, linezolid, arylomycins, etc., 
which are seen as therapeutic alternatives. Furthermore, the rapid emergence of resistance has highlighted the 
importance of antibiotics combination or with other antimicrobial agents, aiming at the reduction of the likelihood of 
resistance development and the enhancement of the effects of individual antimicrobial agents by synergistic action. 
Some of these strategies showed encouraging in vitro results in controlling S. epidermidis biofilms and appear to be 
promising alternatives to standard antibiotics usually used in the treatment of S. epidermidis related infections. 
Due to the increased involvement of S. epidermidis in foreignbody-related infections, the rapid development and 
exhibition of multiple antibiotic resistance as well as its great propensity to lead to persistent, chronic and recorrent 
infections, this pathogen remains a challenge and a subject of study by several research groups and continues to receive 
significant attention. 
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2. Staphylococcus epidermidis biofilm control strategies 
2.1. Traditional antibiotic combination 
As it was already referred, a worrying current problem is the increasing bacterial resistance to traditional antibiotics 
commonly used in hospitals to treat coagulase-negative (CoNS) infections, which is aggravated when the cells are in 
biofilms. Generally, antimicrobial agents alone are ineffective against S. epidermidis biofilms. Rifampicin, a RNA 
synthesis inhibitor, is among the most effective molecules for treating biofilm-related infections [5,6]. However, this 
antibiotic has a high propensity for rapid development of resistance [7,8,9]. This fact makes rifampicin unfeasible as 
monotherapy. A solution to this problem is the combination of antimicrobial agents, avoiding the use of monotherapy. 
Antibiotic combination represents a therapeutic option in the treatment of S. epidermidis infections [10]. In fact, some 
authors demonstrated that, for example, the combination of rifampicin with quinolones or fusidic acid could prevent the 
emergence of rifampicin resistance during therapy [8,11]. 
 Furthermore to avoid resistance, this strategy can also potentiate the effect of individual antimicrobial agents by 
synergic action. Gomes et al. tested the susceptibility of S. epidermidis biofilms in vitro to traditional antibiotics alone 
and in double combinations at breakpoint concentration and demonstrated that there are some combinations that can be 
potentially considered for therapeutic use for an efficient control of S. epidermidis biofilm related-infection (data not 
shown). Rifampicin is always present in these combinations, being rifampicin+gentamicin and rifampicin+clindamycin 
the most active combinations in terms of CFU reduction and with the broadest range of action (Table 1).  
 
Table 1: reduction in log CFU of S. epidermidis biofilm cells after overnight exposure to traditional antibiotics alone and in double 
combination. 
Staphylococcus epidermidis strain Rif Clind Gent Rif+Clind Rif+Gent 
117977 2.37 1.68 0.00 2.65 2.46 
132034 4.01 0.15 0.56 3.68 3.11 
150271 3.15 2.20 0.14 2.73 2.49 
1457 1.58 1.72 0.00 2.46 2.06 
9142 2.42 0.28 0.19 2.64 3.14 
Legend: Rif- rifampicin; Clind- clindamycin; Gent- gentamicin. 
  
After having tested the effect of traditional antibiotics alone and in double combination against S. epidermidis biofilms, 
Gomes et al. studied the effect of the most active combinations on the expression of icaA and rsbU genes, responsible 
for poly-N-acetylglucosamine/polysaccharide intercellular adhesin (PNAG/PIA) production (crucial for biofilm 
formation). The results demonstrated that this combinatorial therapy can cause a lower genetic expression of the two 
specific genes tested, and consequently can reduce biofilm formation recidivism, relatively to rifampicin alone [12].    
 
 
 
 
 
 
 
Figure 1. Relative expression of two genes 
responsible by PNAG/PIA formation- icaA and 
rsbU, in a representative S. epidermidis strain (S. 
epidermidis 117977) after overnight exposure to 
antibiotics alone and in combination: 1- positive 
control; 2- rifampicin; 3- clindamycin; 4- 
gentamicin; 5- rifampicin + clindamycin; 6- 
rifampicin + gentamicin.  
 
 
 
 
 Comparing rifampicin and both combinations tested by Gomes et al., it was observed that all of them have a similar 
effect against S. epidermidis biofilms (Table 1). However, taking into consideration the expression of the two genes 
tested, those authors concluded that biofilm cells treated with rifampicin overexpressed both genes responsible by 
PNAG/PIA formation, relatively to the positive control and both antibiotic combinations tested (Figure 1). This possible 
induction of PNAG/PIA production and consequently biofilm formation can help the bacterial cells in the evasion of the 
immune system. Therefore, this feature can be a possible defense and resistance mechanism adopted by S. epidermidis 
cells to protect its population from antimicrobial agents. The results of Gomes et al. demonstrate that, in addition to 
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avoid the emergence of antibiotic resistance, combinatorial therapy ensures a more efficient control of S. epidermidis 
biofilm-related infections [12]. 
2.2. Natural substances 
The antibiotic resistance ability evidenced by microorganisms growing in biofilms boosted the continuous search for 
novel agents effective in the clearance of cells in this mode of growth. New S. epidermidis biofilm control strategies are 
therefore required to combat these biofilm-related infections/diseases.  
 Nowadays, the interest in natural substances as possible alternatives to antibiotics and new antimicrobial/anti-biofilm 
drugs, namely the natural substances produced by plants, whose bioactive compounds are well known for their 
antimicrobial properties [13], is emerging and is on the focus of some biotechnological companies. The vast range of 
secondary metabolites produced by plants serves to protect them against microbial pathogens and from parasitic 
induced damages. Perhaps it was this fact that has triggered interest in this type of compounds for the treatment of 
infections in humans. 
2.2.1. Farnesol  
Farnesol is a sesquiterpene alcohol found in the essential oils of various plant extracts including: citrus fruits [14,15], 
Pluchea dioscoridis, Zea mays and Pittosporum undulatum, possibly protecting these plants from parasitic induced 
damages [16,17], and can also be produced by several organisms such as the yeast Candida albicans. It was used during 
many years for therapeutic purposes, cosmetics, food flavourings, and food preservatives. Regarded as a molecule with 
promising antimicrobial properties, it was studied as a possible antimicrobial agent against many microorganisms and 
as a potential alternative to antibiotics. Derengowski et al. (2009) and Jabra-Rizk et al. (2006) were some of the authors 
that signaled its potential use as antimicrobial agent. Studies evidenced that farnesol affects the growth of many bacteria 
and fungi. One example is the coagulase-positive staphylococci Staphylococcus aureus, where farnesol demonstrated to 
inhibit biofilm formation and compromised cell membrane integrity [18,19]. Several works suggested that the main 
target of farnesol is the cell membrane, where the damage of this cell structure component might be one of the major 
modes of action of this molecule [18,19]. Exposure to terpene alcohols showed to affect cell membrane of several 
bacteria including S. aureus, Escherichia coli, Listeria monocytogenes, resulting in leakage of K+ ions from cells [18]. 
Gomes and co-authors (2009) also demonstrated the antibacterial effect of farnesol against S. epidermidis biofilms [20]. 
Farnesol (300 M) has evidenced a similar or higher effect of some traditional antibiotics [21]. For instance, it 
compares well with rifampicin, one of the most active antibiotics used in the treatment of S. epidermidis-related 
infections (Figure 2). 
   
 
Figure 2. Scanning electron micrographs of 24 h-
biofilms of S. epidermidis 1457 after treatment 
with farnesol (300 M) or rifampicin (PS- 10 mg 
L-1) for 24 hours. (i) non-treated cells; (ii) 300 M 
farnesol; (iii) rifampicin at peak serum 
concentration.  
 
  
 
Figure 3. Concentration of exopolymers per gram 
of dry weight extracted from S. epidermidis 1457 
biofilm matrix after 24 hours exposure to farnesol. 
*- concentration of exopolymers significantly 
different from untreated biofilm cells. 
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 These authors demonstrated a significant increase of polysaccharide and proteins concentrations after treatment with 
farnesol (300 M) (Figure 3). The justification given for this fact was the possible bursting of the cells caused by the 
hydrofobic nature of farnesol that favours its accumulation in the membrane, possibly causing membrane disruption and 
consequently the release of cellular content, as also supported by other studies [18,19]. 
 Since S. epidermidis cells are able to 
acquire antibiotic resistance, they 
possibly could also develop mechanisms 
of resistance to farnesol. Accordingly, it 
was crucial to determine the cell ability 
to acquire tolerance/resistance to this 
antimicrobial agent. Subjecting 
consecutively S. epidermidis cells to sub-
inhibitory and inhibitory concentrations 
(30 and 100 M, respectively) of 
farnesol no significant reduction was 
observed in the antibacterial effect and 
susceptibility of cells to farnesol over 
time (Figure 4). However, it was 
observed a rapid adaptation of cells after 
the initial contact to farnesol, but since 
this adaptation was not progressive we 
concluded that this behavior is 
reversible, and therefore a case of 
tolerance and not resistance.  
Figure 4. CFU inhibition expressed in percentage, by farnesol on S. 
epidermidis 1457 cells over five consecutive days. Control represents 
non-treated cells.   
2.2.2. N-acetylcysteine (NAC) 
NAC is an amino acid with strong antioxidant, antimucolytic and antibacterial properties, and is produced within the 
human body. N-Acetylcysteine decongests lungs, boosts immune response, detoxifies many toxins and poisons and 
boosts glutathione levels. This mucolytic substance is the smallest molecule in use (Molecular weight: 163.19) [22], 
being nowadays used in the treatment of chronic bronchitis [23], cancer and paracetamol intoxication [24,25]. Its effect 
in biofilms has been tested in several bacteria such as Staphylocccus aureus, Escherichia coli [26], Enterobacter 
cloacae, Klebsiella pneumoniae [27], and several other gram-positive and gram-negative bacteria [23]. In addition to 
reducing biofilm formation, and consequently reduce bacterial infections [23], several authors observed that NAC is 
able to reduce bacterial adhesion and release bacteria already adhered to the surfaces tested [23,24,28].  
 Biofilms are composed primarily of microbial cells and EPS. EPS may account for 50-90% of the total organic 
carbon of biofilms and can be considered the primary matrix material of the biofilm [29]. Since extracellular 
polyssacharides are the main compounds in biofilm matrices, namely in S. epidermidis, antimicrobial substances able to 
disrupt or inhibit EPS are of major interest. Taking this into consideration and knowing that NAC has mucus-dissolving 
properties, the effect of NAC in biofilm cells of S. epidermidis was also assessed [30]. In addition, and with the 
objective of trying to find any synergistic action between non-antibiotic substances with different modes of action and 
targeting different biofilm components, the combinatorial effect of NAC and farnesol was also tested (Figure 5). NAC 
per se at a concentration of 10xMIC (40 mg L-1) exhibited a high inhibitory effect against S. epidermidis biofilm cells 
(Figure 5a and b), achieving reductions in the number of viable cells of circa of 4 log [30]. In figure 5b it is possible to 
observe the effect of NAC on the biofilm matrix (desintegration of biofilm matrix) and biofilm cell viability. Although 
farnesol and NAC act differently, no synergy was observed when tested together (Figure 5a). As observed by other 
researchers, NAC decreased biofilm formation and reduced the formation of extracellular polysaccharide matrix, while 
promoting the disruption of mature biofilm [31]. NAC has demonstrated not only to reduce adhesion but also to detach 
bacterial cells adhered to surfaces and to inhibit bacterial growth in vitro [23]. The possible action of NAC in the 
biofilm matrix can result in the release of cells either individually or in cell clusters, becoming the biofilm and loose 
cells more exposed and susceptible to the human immune system and to other antimicrobial agents. Nevertheless, the 
bactericidal effect of NAC is attained at a concentration that is probably too high (40 mg L-1) to be administered safely 
but this does not invalidate its use as a lock solution therapy. 
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Figure 5. a) Viable cell number reduction (in log CFU) of 24 h S. epidermidis 1457 biofilm 
after 24 h treatment with farnesol and NAC alone and in combination. Legend: 1- NAC 
(1×MIC-4 mg L-1); 2- NAC (10×MIC-40 mg L-1); 3- Farnesol (300 M); 4- Farnesol (300 
M)+NAC (1×MIC) and 5- Farnesol (300 M)+ NAC (10×MIC). b) Scanning electron 
microscopy images of 24 h biofilm not exposed to any antimicrobial agent (positive control) 
(i) and after 24 h exposure to NAC at 10 ×MIC (ii).  
2.2.3. Essential oils and other natural substances 
Essential oils are described as molecules with antimicrobial activity against a wide range of microorganisms [32]. An 
important characteristic of essential oils and respective components is their hydrophobicity, which enables them to 
partition into and disturb the lipid bilayer of the cell membrane, rendering them more permeable to protons. Extensive 
leakage from bacterial cells or the exit of critical molecules and ions ultimately leads to bacterial cell death [33]. On the 
other hand, another important advantage of the usage of essential oils as alternative to antibiotics is that bacteria are not 
able to acquire resistance to this kind of molecules [34]. 
 One example is cinnamon oil whose predominant active compound is cinnamaldehyde, and which is frequently used 
in food industry. This molecule is also described by Chang et al. (2001) as beneficial to human health and as having a 
potential use for medical purposes [35]. Nuryastuti et al. (2009) have shown the potential antibacterial action of this 
compound against S. epidermidis biofilm cells [36]. Cinnamon oil showed antimicrobial activity against S. epidermidis 
biofilms, translated by detachment and death of existing biofilms. The same authors, also reported a significant 
overexpression of the icaA gene, responsible by PNAG/PIA formation and therefore strongly related with biofilm 
formation, after exposure to sub-minimum inhibitory concentrations of cinnamon oil, pointing to a potential action of 
this molecule as an inducer of biofilm formation in clinical S. epidermidis strains. In fact, it has already been reported 
by several researchers that conditions potentially toxic for bacterial cells, including high levels of osmolarity, 
detergents, urea, ethanol, oxidative stress, and the presence of sub-MICs of some antibiotics, can be inducers of biofilm 
formation [37-39]. 
 However and since cinnamon oil was able to inhibit biofilm formation, detach existing biofilms, and have a strong 
bactericidal effect on S. epidermidis biofilms, it was signaled by Nuryastuti et al. (2009) as an effective antimicrobial 
agent to combat S. epidermidis biofilms [36]. Based in other reports, and compared to twenty other essential oils used in 
traditional medicine, cinnamon oil did exhibit the most potent bactericidal effect against different important pathogens 
[33,40]. 
 Berberine is an isoquinoline-type alkaloid isolated from Coptidis rhizoma, a major herb widely used in chinese 
herbal medicine [41], and in other herbs. This molecule has been pointed as a potential antimicrobial agent against a 
wide range of microorganisms such as bacteria, fungi and viruses. An advantage of using this molecule is its low 
toxicity and mutagenicity to human cells, pointing to their potential use as therapeutic alternative to traditional 
antibiotics. To the authors’ knowledge, the only study focusing the effect of berberine on bacterial biofilms is the one 
by Wang et al. (2009) [1]. These authors defend that berberine interacts with bacterial DNA inhibiting the transcription 
of target genes [1]. Although the mechanism of uptake and transport of berberine in S. epidermidis is not fully 
understood, Severina et al. (2001) showed that this molecule penetrates phospholipid bilayers and can be 
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electrophoretically accumulated inside S. aureus cells [42]. Wang et al. (2009) demonstrated that berberine has a 
bacteriostatic effect on S. epidermidis cells, preventing adhesion and consequently significantly inihibiting biofilm 
formation [1]. These results indicate the possible use of this natural substance as an adjuvant therapeutic agent for the 
prevention of S. epidermidis biofilm-mediated infections. 
 Plants belonging to the genus Salvia have been used for years in natural medicines for treatment of several human 
disorders/diseases [43]. One example is the specie Salvea sclarea L., cultivated in many european countries, which 
secondary metabolites, essential oil and diterpenoids, showed various biological activities. Salvipisone is a diterpenoid 
isolated from Agrobacterium rhizogenes transformed roots of Salvia sclarea. Its activity against S. epidermidis biofilms 
was evidenced by the inhibition of cell adhesion and consequently the inhibition of biofilm formation. Salvipisone was 
shown to be bactericidal to this gram-positive pathogen, reducing significantly the number of viable biofilm cells. This 
compound was strongly active against S. epidermidis biofilms, being among the potential anti-S. epidermidis biofilm 
agents [13].  
 Casbane diterpene (CD) is a natural compound produced by Croton nepetaefolius, a native plant from northeastern 
Brazil [44]. This plant is widely used for medicinal purposes [45]. Testing the effect of this molecule in S. epidermidis 
biofilms, Carneiro et al. (2011) demonstrated that casbane diterpene affected biofilm formation by this pathogen, 
exhibiting an excellent antibacterial profile on gram-positive bacteria, namely on S. epidermidis. The possible 
mechanism of action, suggested by the previous research group, and supported by CD chemical characteristics, 
hidrophobicity and polarity, was the non-specific interaction of casbane diterpene with cell membrane [44]. The 
interaction with phospholipids, consequent destabilization of non-covalent interactions between the fatty acids of the 
lipid bilayer, possibly interfere with cellular development of S. epidermidis bacteria, disturbing several cellular 
processes such as permeability, cell growth and division. 
2.3. New generation of antibiotics 
Several recently available antibiotics (antibiotics of novel generation) have been developed in order to overcome the 
emergence of antibiotic resistance. Some examples of these new agents are: linezolid, daptomycin, tigecycline, 
quinupristin/dalfopristin and dalbavancin. Some authors defend that these antibiotics may be suitable for treatment of 
foreign-body infections, caused by sessile and biofilm-producing bacteria such as S. epidermidis, and may provide 
alternatives for monotherapy or combination therapy with rifampicin [7].  
We compared the susceptibility of S. 
epidermidis biofilm cells to rifampicin, 
widely used in the prevention/treatment of 
indwelling medical device infections, with 
daptomycin (lipopeptide) and linezolid. 
Rifampicin and daptomycin showed a 
similar effect against S. epidermidis 
biofilms (CFU log reductions of circa of 3 
log). Linezolid demonstrated a slightly 
lower activity than both antibiotics 
mentioned previously (Figure 6). Taking 
into consideration these results, we 
concluded that daptomycin can be strongly 
considered a potential alternative to 
rifampicin in serious infections where 
rifampicin resistance becomes prevalent and 
a possible therapeutic strategy to control S. 
epidermidis-associated infections.  
 
Figure 6. Viable cell number reduction (in log CFU) of 24 h S. epidermidis 1457 biofilm after 24 h treatment with 1- rifampicin; 2- 
daptomycin; 3- linezolid, at peak serum concentration (10, 95 and 18 mg L-1, respectively).  
 
 Consistent with our results, other experimental data, regarding the effect of antibiotics on staphylococcal biofilms, 
also showed promising results for some of novel antibiotics: daptomycin, tigecycline and linezolid significantly reduced 
the biofilm burden and the number of viable bacteria within the biofilms [46]. Daptomycin and tigecycline (a 
glycylglycine) have been pointed as alternative agents to vancomycin, a standard antimicrobial agent used in the 
treatment of methicillin-resistant Staphylococcus aureus and S. epidermidis associated infections [47,48], presenting 
excellent activity against both Staphylococci species. Tigecycline demonstrated to be active against a range of 
multiresistant organisms and is bactericidal against biofilm-related Staphylococcus epidermidis at a lower minimal 
bactericidal concentration (MBC) than that of vancomycin and daptomycin [49]. Quinupristin/dalfopristin was also 
active against S. epidermidis biofilm cells [50]. In vitro and in vivo assays point to the potential usefulness of 
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dalbavancin for the treatment of foreign-body infections [51], caused by sessile and biofilm-producing bacteria such as 
S. epidermidis.   
 On the other hand, although alternative agents such as linezolid, tigecycline, daptomycin and 
quinupristin/dalfopristin are claimed to be highly effective against biofilms [52], and presented good results against S. 
epidermidis in the biofilm mode of growth, their use has some disadvantages and some studies presented controversial 
results in comparison with  those mentioned previously. Firstly, apart from their very high cost, they are in clinical use 
for a short time only and so the extent of their toxicity is yet to be experienced [53]. Additionally, the chance to treat 
implant infections is very low once infection involving bacterial biofilms has begun [53]. Up to now, debridement and 
removal of a heavily infected implant plus antimicrobial treatment are the only options [54]. However, more 
experimental work has to be performed to investigate the level of debridement and the optimal type and dosage of 
antimicrobial substance needed for the eradication of the bacterial biofilm [44], specifically of S. epidermidis. 
Moreover, Hajdu et al. (2009) observed that no significant reduction in S. epidermidis biofilms CFU was achieved with 
daptomycin and tigecycline, not even at the highest concentrations tested (128 × MIC). Generally these concentrations 
are far beyond any concentration that can be achieved after administration of standard therapeutic doses [53]. Aslam et 
al. (2007) also tested the effect of tigecycline and after 12 hours of treatment only a mean reduction of the bacterial 
growth by 2 log counts was obtained, notably using a concentration of 1mg mL-1 (1,000 fold higher than its MIC for the 
organisms tested in the planktonic phase) [31]. In this case, the concentration of tigecycline expected to be in human 
serum after standard dosing is 2 mg L-1 [53]. Utilizing high doses of antimicrobials to eradicate biofilm has had limited 
success in the clinical practice [31]. Based on these controversial results, the use of such new antibiotics to combat 
infections caused by S. epidermidis does not seem very encouraging. In addition, resistance to some of this novel 
antibiotics, including linezolid [55-57], and tigecycline, also occurs, although rarely [58]. Taking this into 
consideration, the potential use of new antibiotics as strategies to control S. epidermidis infections leaves some doubt 
and the use of antibiotic/antimicrobial agents combinations seems to represents nowadays a very valid therapeutic 
option. 
2.4. Antimicrobial agents combination 
Considering that farnesol acts in the cells membranes, it will be expected that this compound would non-specifically 
potentiate the permeability of bacterial cells to certain exogenous chemical compounds, including antimicrobials, 
facilitating antibiotic entry and aiding in the clearance of S. epidermidis biofilms. This was observed by Jabra-Rizk et 
al. (2006) in a study where farnesol acted in synergy with gentamicin, pointing to a possible application of this 
molecule as an adjuvant therapeutic agent [18]. The interaction of farnesol with some antibiotics, such as vancomycin 
(cell wall synthesis inhibitor), tetracycline (protein synthesis inhibitor) and rifampicin (RNA synthesis inhibitor), with 
different modes of action was also studied by Gomes et al. However, no synergy between farnesol and the antibiotics 
tested was detected (data not shown) [21]. 
 
 We also investigated the in vitro 
combined effect of linezolid (1 mg L-1) 
and NAC (40 mg L-1) on S. epidermidis 
biofilms. This combination exhibited a 
significant synergistic effect (Figure 7) 
and this was the most biocidal treatment 
herein mentioned, having promoted a 5 
log reduction in the number of biofilm 
viable cells. For all the advantages of the 
combinatorial therapy above referred and 
the excellent inhibitory effect obtained, 
this combination seems to be a potential 
candidate in the combat of infections 
caused by S. epidermidis biofilms, at least 
in lock solution therapy. 
 
 
Figure 7. Viable cell number reduction (in log) of 24 h S. epidermidis 1457 
biofilm after 24 h treatment with 1- Lin (MIC-1mg L-1); 2- NAC (10×MIC-
40mg L-1); 3- Lin (MIC)+NAC(10×MIC).  
 
 The susceptibility of S. epidermidis biofilm cells to tigecycline+NAC was studied by Aslam et al. (2007). These 
authors showed that this combination significantly decreased the viable biofilm-associated bacteria and was synergistic 
for S. epidermidis [31]. A possible explanation to this increased effect may be due to the degradation of the extracellular 
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polysaccharide biofilm matrix by NAC [23, 26], becoming the biofilm-associated cells more susceptible to the action of 
tigecycline [31].    
 Nuryastuti et al. (2009) investigated the synergy between cinnamon oil and gentamicin, triclosan, and chlorhexidine 
on S. epidermidis biofilms. They showed that this essential oil has synergistic activity with all the antimicrobial agents 
tested. As comproved by Nuryastuti et al. (2009) the synergystic activity between an essential oil and an antimicrobial 
agent may be due to their actions on either different or similar targets of bacterial cells [36]. The synergistic activity of 
cinnamon oil with other antimicrobial agents could be beneficial in clinical settings, for example, to improve skin 
antisepsis and to eliminate antimicrobial-resistant S. epidermidis strains [59]. One of the advantages of the use of 
cinnamon oil in combinatorial therapy with a relative expensive antimicrobial agent is its low price, which can 
significantly lower the therapeutic cost [36]. 
3. Conclusions 
Although new antibiotics have been developed in order to overcome the growing problem of bacteria resistance,  
namely of S. epidermidis, this does not seem to be sufficient due to the rapid emergence of resistance caused by the 
overuse of antibiotics, the high diversity of these bacteria, their short replication time, the horizontal transfer of 
resistance genes, etc. Another problem to take into consideration is the strain diversity and response to the different 
antimicrobial agents. The effect of antimicrobial agents is highly strain-dependent and the rate of success will be 
strongly dependent on the infectious S. epidermidis strain. The only way to avoid or slow the rapid emergence of 
resistance remains the prudent use of antibiotics and/or the development of alternatives to control S. epidermidis-related 
infections. Therefore it is still needed a continuous search for new strategies against S. epidermidis biofilms. Overall, 
there are some promising therapeutic strategies, such as some natural compounds and antimicrobial agents 
combinations, that can be possibly used for medical purposes especially in the combat of infections caused by S. 
epidermidis biofilms. 
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